Optimal Screening for Genetic Diseases

No 2008:2, HERO Online Working Paper Series from University of Oslo, Health Economics Research Programme

Abstract: Screening for genetic diseases is performed in many regions and/or ethnic groups where there is a high prevalence of possibly malign genes. The propagation of such genes can be considered dynamic externality. Given that many of these diseases are untreatable and give rise to truly tragic outcomes they are a source for societal

concern and the screening process should perhaps be regulated.

The present paper incorporates a standard model of genetic propagation into an economic model of dynamic management. The paper derives cost benefit rules for optimal screening. The highly non-linear nature of genetic dynamics gives rise to perhaps surprising results which include discontinuous controls and threshold effects. One insight is that a screening program, if at all in place at all at some point in time, should screen all individuals.

Keywords: Screening programme; Genetic diseases; Dynamic management (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
Pages: 30 pages
Date: 2009-06-02
New Economics Papers: this item is included in nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.hero.uio.no/publicat/2008/2008_2.pdf (application/pdf)

Related works:
Journal Article: Optimal screening for genetic diseases (2014)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:oslohe:2008_002

Access Statistics for this paper

More papers in HERO Online Working Paper Series from University of Oslo, Health Economics Research Programme HERO / Department of Health Management and Health Economics P.O. Box 1089 Blindern, N-0317 Oslo, Norway. Contact information at EDIRC.
Bibliographic data for series maintained by Kristi Brinkmann Lenander ().